DECN Litigation Victory Against Johnson + Johnson, Launches Foothold in On-Line Retail Markets for Its Popular "Gen" Products

LOS ANGELES, CA--(Marketwired - Aug 23, 2016) - Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip™ 50 and the GenUltimate!™ glucose test strips, both designed to work with the market leading Johnson & Johnson's ("J&J") LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure!™ and GenChoice!™ glucose test strips targeted to the U.S. and/or developing world markets today conveys positive results from the execution of the marketing plan for the "Gen" family of glucose testing products.

Intrinsic to the attainment of the company's identified revenue goals was the attainment of a series of successfully executed tactics running both concurrently and, in some instances, consecutively. The central and initial hurdle was the complete defeat of J&J in its efforts to exclude our participation in a free and fair competitive marketplace. During the product market hiatus driven by that litigation, the company utilized the time and opportunity to prepare for a re-launch of Genstrip 50 while simultaneously developing a suite of new market additions, both in and out of the blood glucose test strip market segment. Those new line additions include GenUltimate!, currently sold in ever more market niches and other unique line expansions that will be formally introduced beginning with the fourth quarter of 2016.

Keith Berman, PEO and CFO of DECN, commented, "As relayed in prior communications, Decision Diagnostics and Pharma Tech engaged the lengthy J&J/Lifescan litigation battles solely to regain the right to legally sell the Genstrip 50 and its derivative products without restraint or intimidation. Now that those legal conflicts have been concluded with prejudice via the Federal courts as of May 20, 2016, we have enthusiastically begun implementing the marketing plan for our 'Gen' products. The first target in our post-litigation market strategy entailed the capture of new on-line retailer agreements and in some instances the re-capture of agreements we were forced to delay."